China Recombinant Lispro Insulin Market Report 2021-2025 with Situation of Diabetes and Overview of the Antidiabetic drug Market in China
Share this article Share this article ResearchAndMarkets.com's offering. By the end of 2020, the number of diabetic patients in China has exceeded 1.13 billion. For patients with type 1 diabetes, insulin is the only effective treatment. In addition, 30% to 40% of patients with type 2 diabetes will eventually become insulin-dependent. With the increase in the number of diabetic patients, the market size of diabetes treatment drugs in China is also rising, among which third-generation insulins such as insulin glargine, insulin aspart, and lispro insulin occupy a relatively high market share. Re...
Source: prnewswire.com